Elliot Stieglitz, MD
|School||UCSF School of Medicine|
|Address||1450 Third St|
San Francisco CA 94158
|Stony Brook ||MD||2008||School of Medicine|
|New York Presbyterian - Weill Cornell||2011||Pediatric Residency|
|University of California, San Francisco||2014||Pediatric Hematology Oncology Fellowship|
|St. Baldrick's Foundation Fellowship||2014
||2016||Fellow in Clinical Research |
|Alex's Lemonade Stand Foundation||2015
||2017||Young Investigator Award|
|American Cancer Society||2016
||2017||Individual Research Award|
||2016||Translational Research Training in Hematology|
Juvenile myelomonocytic leukemia (JMML) is a blood cancer that affects young children and is often difficult to diagnose and treat. Currently available therapies cure only half of patients, with some children experiencing an aggressive disease course while a rare group get better with very little treatment. We have now shown that presence of secondary mutations via deep sequencing or droplet digital PCR predicts a poor outcome. We are currently working on developing a methylation based assay to predict both good and poor responders at diagnosis.
We are also running a clinical trial through the Children's Oncology Group for patients with relapsed and refractory JMML. This trial will test the safety and efficacy of the oral MEK inhibitor, trametinib. This trial is based on extensive pre-clinical testing and a strong genomic rationale. This trial marks an important step towards more effectively treating patients with Ras driven leukemia using targeted agents.
Derived automatically from this person's publications.
People in Profiles who have published with this person.
People who share related concepts with this person.